BRISBANE, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Humanigen, Inc. (OTCQB:HGEN), a biopharmaceutical company pursuing cutting-edge science to develop its proprietary monoclonal antibodies for immunotherapy and oncology treatments, announced today that Cameron Durrant, M.D., chairman and CEO, will present a company overview at two upcoming investor conferences.

Dr. Durrant will outline Humanigen’s continuing transformation into a cutting-edge science biotechnology company by repositioning and developing its proprietary monoclonal antibodies, including lead asset lenzilumab for the potential prevention of neurotoxicity associated with chimeric antigen receptor T-cell (CAR-T) therapy.

Details of the presentations follow:

• NobleCon14 - Noble Capital Markets’ 14th Annual Investor Conference
  Presentation date: Jan. 30, 2018
  Presentation time: 2:30 p.m. EST
  Location: Studio 3, W Hotel in Fort Lauderdale, Fla.
  
  A high-definition, video webcast of this presentation will be available on January 31, 2018. To view the webcast, click this webcast link or visit the Investors section of the Humanigen website at https://ir.humanigen.com
  
  The webcast will also be available as part of a complete catalog of presentations at www.noblecapitalmarkets.com and www.nobleconference.com. Viewing requires the Microsoft SilverLight viewer. The webcast and presentation will be archived on Humanigen’s website and the Noble websites for 90 days following the event.
  
  
• 2018 BIO CEO & Investor Conference
  Presentation date: Feb. 12, 2018
  Presentation time: 2:45 p.m. EST
  Location: Wilder Room, New York Marriott Marquis in New York City, NY

In addition, senior management will hold one-on-one meetings at the conferences. To schedule a meeting, please use the investor contacts below.

About Humanigen 

Humanigen, Inc. is a biopharmaceutical company pursuing cutting-edge science to develop its proprietary monoclonal antibodies for immunotherapy and oncology treatments. Derived from the company’s Humaneered® platform, lenzilumab and ifabotuzumab are lead compounds in the portfolio of monoclonal antibodies with first-in-class mechanisms. Lenzilumab, which targets granulocyte-macrophage colony-stimulating factor (GM-CSF), is in development as a potential medicine to make chimeric antigen receptor T-cell (CAR-T) therapy safer and more effective, as well as a potential treatment for rare hematologic cancers such as chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML). Ifabotuzumab, which targets Ephrin type-A receptor 3 (EphA3), is being explored as a potential treatment for glioblastoma multiforme (GBM) and other deadly cancers. For more information, visit www.humanigen.com.

CONTACT:

Investors:
Cameron Durrant
650-243-3181
cdurrant@humanigen.com

Mike Cole
O: 949-259-4988
C: 949-444-1341
mike.cole@mzgroup.us

Media:
media@humanigen.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.